STAT+: Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited
Eli Lilly (LLY) announced plans to lower the wholesale price of certain insulin products by an additional 40% in January 2022, the latest bid by a drug maker to combat criticism that the cost of these life-saving diabetes treatments are out of reach for too many patients.
The move involves dropping the price of Insulin Lispro Injection in the U.S. to $82.41 for individual vials and $159.12 for a pack of five pens, which the company maintained will be 70% of the cost of Humalog U-100, a brand-name version of the product. The new wholesale price, which will lower the wholesale price for the product, will apply to all so-called authorized generic versions of Humalog that Lilly sells.
